Boceprevir Approval Means Better Hep C Treatment Finally Available
May 16, 2011
Boceprevir Wins FDA Approval to Treat Hepatitis C
By Emily P. Walker, Washington Correspondent, MedPage Today
Published: May 13, 2011
WASHINGTON — The FDA has approved the investigational drug boceprevir (Victrelis), to be used in combination with peginterferon and ribavirin, to treat hepatitis C genotype 1.
Boceprevir, made by Merck, will be the first HCV protease inhibitor to reach market and is expected to be a major advance in treating the disease, which affects between three and four million people in U.S.
Continue reading this entire article:
Those with Hepatitis B or C Need Hepatitis A Immunity
Could New HCV Drugs Excessive Pill Intake Hinder Compliance?